Pharmaceuticals

Surge In Prevalence Of Rare Genetic Diseases Fueling The Growth Of The Market Due To Improving Diagnostics And Increasing Awareness Is Supporting Development Across The Farber’s Disease Market

May 19, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Farber’s Disease Market Increase Between 2026 And 2030?

The farber’s disease market has experienced robust expansion in recent years. It is projected to expand from $1.98 billion in 2025 to $2.1 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. Factors such as rare disease identification, pediatric genetic testing, supportive care protocols, hospital specialization, and research funding are credited for the growth observed in the historic period.

The farber’s disease market is expected to experience significant expansion in the coming years. It is projected to reach $2.61 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 5.6%. This anticipated growth throughout the forecast period is driven by factors such as advancements in gene therapy pipelines, incentives for orphan drugs, the implementation of early diagnosis programs, the establishment of rare disease registries, and the development of advanced genetic tools. Major trends for this period include an increased focus on rare pediatric disorders, the broadening of gene therapy research, greater adoption of supportive care, the emergence of multidisciplinary treatment approaches, and improvements in genetic diagnostics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24533&type=smp

What Important Drivers Are Powering The Farber’s Disease Market Growth?

The farber’s disease market is anticipated to expand due to the increasing occurrence of rare genetic diseases. These inherited conditions, stemming from DNA mutations, impact a minimal portion of the population. Their rising prevalence is attributed to enhanced diagnostic methods, which facilitate earlier and more precise detection of conditions previously missed or misidentified. Farber’s disease plays a role in addressing this trend by acting as a framework for creating specific treatments and furthering research into enzyme replacement therapies for extremely rare disorders. For example, the European Commission (EC), a Belgium-based government entity, reported in February 2023 that approximately 36 million individuals in the European Union suffer from a rare disease; the EU is home to over 6,000 distinct rare diseases, with roughly 80% originating genetically. Consequently, the increasing incidence of rare genetic diseases is stimulating the growth of the farber’s disease market. The farber’s disease market is set to experience growth due to rising investments in clinical trials. These trials are human research studies designed to assess the safety, efficacy, and results of medical interventions, including medications, therapies, or devices. The surge in clinical trial funding stems from a heightened demand for novel treatments, spurred by progress in medical science, personalized medicine, and the pressing necessity to address unmet health requirements. Farber’s disease contributes to this trend by underscoring the critical need for research focused on rare and overlooked genetic conditions. For instance, Citeline, a US-based pharma intelligence solutions provider, reported that in October 2024, TrialTrove recorded 9,959 Phase I–III clinical trials initiated in 2024, exploring at least one drug, marking a 9.4% increase compared to 2023. Thus, the escalating investment in clinical trials is a key factor driving the expansion of the farber’s disease market.

How Is The Farber’s Disease Market Examined Through Segment Analysis?

The farber’s disease market covered in this report is segmented –

1) By Type Of Farber’s Disease: Classical Farber’s Disease, Non-Classical Farber’s Disease

2) By Treatment: Enzyme Replacement Therapy, Symptomatic Treatment, Gene Therapy, Bone Marrow Transplant, Supportive Care

3) By Clinical Symptoms: Joint Involvement And Deformities, Hearing Loss, Respiratory Distress, Dermatological Manifestations

4) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Classical Farber’s Disease: Type 1 Severe Infantile Form, Type 2 Intermediate Childhood Form, Type 3 Juvenile-Onset Form

2) By Non-Classical Farber’s Disease: Type 4 Neurological Predominant Form, Type 5 Visceral Predominant Form, Type 6 Cardiopulmonary Involvement Form

Which Firms Are Competing In The Farber’s Disease Market?

Major companies operating in the farber’s disease market are National Institutes of Health (NIH), U.S. National Institute of Neurological Disorders and Stroke (NINDS), Mount Sinai Icahn School of Medicine, Cincinnati Children’s Hospital Medical Center, University of Pennsylvania Gene Therapy Program, Seattle Children’s Research Institute, Genethon (AFM-Téléthon), Sarepta Therapeutics Inc., REGENXBIO Inc., Abeona Therapeutics Inc., Rocket Pharmaceuticals Inc., Passage Bio Inc., Spark Therapeutics Inc., Takeda Rare Disease Research, Orchard Therapeutics plc, Avrobio Inc., bluebird bio Inc., JCR Pharmaceuticals Co. Ltd., Protalix BioTherapeutics Inc., Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., Amicus Therapeutics Inc.

Access The Complete Farber’s Disease Market Report:

https://www.thebusinessresearchcompany.com/report/farbers-disease-global-market-report

Which Region Accounts For The Highest Share Of The Farber’s Disease Market?

North America was the largest region in the farber’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the farber’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Farber’s Disease Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24533&type=smp

Browse Through More Reports Similar to the Global Farber’s Disease Market 2026, By The Business Research Company

Rare Disease Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

Rare Diseases Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

Rare Kidney Diseases Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795